Letters to the Editor

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase 1b study

Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX
Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA
Division of Hematology and Medical Oncology,Meyer Cancer Center, Weill Cornell Medicine, New York, NY
Division of Hematology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH
Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Winship Cancer Institute of Emory University, Atlanta, GA
Department of Haematology, Plymouth University Medical School, Plymouth
AstraZeneca, South San Francisco, CA
AstraZeneca, South San Francisco, CA
AstraZeneca, South San Francisco, CA
AstraZeneca, South San Francisco, CA
AstraZeneca, Gaithersburg, MD
Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester
Haematologica Early view Jul 8, 2021 https://doi.org/10.3324/haematol.2021.278654